OakChart

GRI Bio Inc

GRIHealthcare·Biotechnology·USA·Nano·NASD·Nov 12 • 3:59 PM ET

1.82-0.01 (-0.55%)
2026-11-13 06:16 CET
Market cap
$3.98M
Revenue, TTM
0.00 USD m
Net income, TTM
-9.66 USD m
Free cash flow, TTM
-10.42 USD m
EPS diluted, TTM
-43.74
Price / earnings
-
Compare

Price

GRI against its 20, 50 and 200-day averages
Terms2050200Earnings
Patternshover a marker to name it
RS 0Sales 0.00Price0.000.0010.0020.003.7M7.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GRIclose 1.8220-day 1.5850-day 1.78200-day 2.051.82

97.2% under the 52-week high of 64.12 on 24 Nov 2025. 52-week low 1.36 on 31 Jul 2026. Last 15 sessions, 44.9% high to low

Volume 0.21× normal · the line is the 50-bar volume average

Setup. RS line 0
CANSLIM 3 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 2 of 5 — fails: 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 1 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 200-Day Simple Moving Average: Price above SMA200
Growth 3 of 4 — fails: Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 0 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50% — not on the tape: Float: Under 100M
Accumulation 1 of 4 — fails: Institutional Ownership: Over 30%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K

Profile

GRI
52-week range, 1% of the way up
1.3664.12

GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

Employees4
IPOFeb 10, 2021
Beta-1.10
ATR, 14d0.17
Rel volume0.21
Insider own0.00%
Inst own4.82%

Snapshot

6 groups

Valuation

Index-
Market Cap$3.98M
Enterprise Value-6.93M
Income-9.66M
Sales0.00M
Book / share4.70
Cash / share5.01
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees4
IPOFeb 10, 2021

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book0.39
Price / cash0.36
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio10.30
Current Ratio10.30
Debt / equity0.00
Long-term debt / equity0.00
Options and shortNo / Yes

Earnings

Earnings / share-43.74
Earnings next year-2.00
Earnings next quarter-0.84
Earnings this year96.93%
Earnings next year46.60%
Earnings growth, 5 years88.82%
Past earnings growth97.03% 83.24%
Past sales growth- -
Earnings vs last year93.96%
Sales vs last year-
Earnings vs last quarter97.52%
Sales vs last quarter-
EarningsAug 19
Surprise23.85% -

Ownership

Insiders own0.00%
Insider trades-
Institutions own4.82%
Institution trades252.37%
Return on assets-113.27%
Return on equity-142.02%
Return on capital-93.96%
Gross Margin-
Operating margin-
Profit Margin-
20-day average15.39%
50-day average2.39%
200-day average-11.30%

Technical

Shares out2.19M
Shares floating-
Short / float-
Short ratio0.29
Short interest0.07M
52-week high64.12 -97.2%
52-week low1.36 +33.8%
Volatility13.47% 9.88%
Average range0.17
Strength index56.26
Market sensitivity-1.10
Relative volume0.21
Avg Volume226.41K
Volume48,032

Performance

Perf Week17.42%
Perf Month30.00%
Perf Quarter8.98%
Perf Half Y-15.35%
Perf YTD-73.66%
Perf Year-96.52%
Perf 3Y-100.00%
Perf 5Y-100.00%
Perf 10Y-
Recommendation1.00
Target Price18.50
Prev Close1.83
Price1.82
Change %-0.55%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Dec 09, 2024InitiatedH.C. WainwrightBuy$10+449.5%

Peers

Mkt cap
TickerCompanyMkt cap
RNTXRein Therapeutics Inc48.31M
TVRDTvardi Therapeutics Inc15.40M
PLRXPliant Therapeutics Inc45.82M
AVLNAvalyn Pharma Inc1.36B
VCREVicore Pharma Holding AB ADR309.48M
CMMBChemomab Therapeutics Ltd ADR10.15M
GYREGyre Therapeutics Inc495.88M
GALTGalectin Therapeutics Inc316.67M
TLSATiziana Life Sciences Ltd78.33M
EDSAEdesa Biotech Inc28.11M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.79B

News

latest 14 of 200
  • GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit (GlobeNewswire)
  • GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars (GlobeNewswire) -30.56%
  • GRI Bio Featured in "Why Now" On-Demand Video Webcast (GlobeNewswire) +8.38%
  • GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 (GlobeNewswire) +8.48%
  • GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis (GlobeNewswire) -18.97%
  • GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase (GlobeNewswire) +5.42%
  • GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline (GlobeNewswire)
  • GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions (GlobeNewswire)
  • GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment (GlobeNewswire)
  • GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial (GlobeNewswire) -17.05%
  • GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights (GlobeNewswire)
  • GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF (GlobeNewswire) -22.74%
  • GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures (GlobeNewswire)
  • GRI Bio Announces Reverse Stock Split (GlobeNewswire) -12.02%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-19-0.910-1.195-0.000.002
2026Q12026-05-14-1.610-1.605-0.000.002
2025Q42026-02-25-13.250-29.260-5.3430.000.002
2025Q32025-11-12-35.840-31.080-35.8770.000.001
2025Q22025-08-13-36.680-36.680-36.7210.000.002
2025Q12025-05-15-162.4-105.98-162.320.000.002
2024Q42025-02-26-218.26-152.32-205.630.000.002
2024Q32024-11-13-318.92-347.48-319.720.000.001
2024Q22024-08-14-2,342--2,3400.00--
2022Q22022-07-28-259,896--265,3410.00--
2022Q12022-05-09-285,886-285,886-502,6000.000.001
2021Q42022-02-14-285,886-285,886-590,5360.000.001
2021Q32021-11-12-233,906--239,754---
2026Q3---0.840--0.002
2026Q4---0.825--0.002
2027Q1---0.980--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-1,390,444--919,980--
2021FY-1,845,262-1,533,386-1,774,4530.000.00
2022FY-896,641--4,629,696--
2024FY-1,550-1,347-1,5460.000.00
2025FY-121.8-164.78-0.000.00
2026FY--3.745--0.00
2027FY--2.000--0.00
2028FY--0.170--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-092000.000.000.00
2026Q3S2026-08-211000.000.000.00
2026Q3S2026-08-192000.000.000.00
2026Q3S2026-05-142000.000.000.00
2026Q3S2026-03-052000.000.000.00
2026Q3S2026-02-251000.000.000.00
2026Q3S2025-11-131000.000.000.00
2026Q3S2025-11-121000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00

Estimate history

EPS, annual-822804.747-660980.503-919979.862-1774452.936-4629696.384-174780.927-1545.772-121.798-43.7402
Period20182019202020212022202320242025TTM
EPS, quarterly-2339.745-319.715-205.627-162.315-36.721-35.877-5.343-1.61-0.91
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000.1000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0000000.0190.4982.186
Period20182019202020212022202320242025MRQ
Shares, quarterly0.0020.0110.0190.0190.0890.1170.4981.5852.186
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.100.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.060.050.07-0.000.00
Gross Profit-0.00-0.00-0.00-0.06-0.05-0.07--0.00-0.00
Selling, General and Administrative Excl. Other9.6811.978.2311.332.199.194.813.154.31
Research and Development4.176.823.773.230.245.193.711.883.51
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-9.68-11.98-8.23-11.39-2.24-9.26-4.79-3.15-4.31
Interest Expense0.000.000.002.080.650.020.030.200.00
Unusual Expense0.000.00-0.00-0.180.330.030.000.110.00
Net Income Before Taxes-9.66-11.96-8.21-13.04-3.22-9.30-4.82-3.46-4.31
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-9.66-11.96-8.21-13.04-3.22-9.30-4.82-3.46-4.31
Net Income From Continuing Operations-9.66-11.96-8.21-13.04-3.22-9.30-4.82-3.46-4.31
Net Income-9.66-11.96-10.12-13.04-3.22-9.30-4.82-3.46-4.31
EPS (Recurring)-5.35-121.80-1,546.09-176,488.79-4,302,294.88-1,770,715.31-919,979.70-645,886.13-822,801.07
EPS (Basic, Before Extraordinaries)-43.74-121.80-1,545.77-174,780.93-4,629,696.38-1,774,452.94-919,979.86-660,980.50-822,804.75
EPS (Diluted)-43.74-121.80-1,545.77-174,780.93-4,629,696.38-1,774,452.94-919,979.86-660,980.50-822,804.75
EBITDA-9.68-11.97-8.23-11.33-2.19-9.19-4.71-3.15-4.31
Non-Operating Income (Expense)0.020.020.030.250.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.600.790.150.390.030.630.150.080.05
Operating Margin-------4,788.00--
Net Margin-------4,822.00--
Shares Outstanding2.190.500.020.000.000.000.000.000.00
Market Capitalization3.983.987.401.143.6940.7441.63--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Selling, General and Administrative Excl. Other1.652.002.663.362.903.051.952.13
Research and Development0.410.361.631.771.881.640.831.13
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.65-2.00-2.66-3.37-2.90-3.05-1.95-2.13
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-1.64-2.00-2.66-3.36-2.89-3.05-1.95-2.12
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.64-2.00-2.66-3.36-2.89-3.05-1.95-2.12
Net Income From Continuing Operations-1.64-2.00-2.66-3.36-2.89-3.05-1.95-2.12
Net Income-1.64-2.00-2.66-3.36-2.89-3.05-3.86-2.12
EPS (Recurring)-0.91-1.61-5.34-35.88-36.72-162.32-205.63-319.72
EPS (Basic, Before Extraordinaries)-0.91-1.61-5.34-35.88-36.72-162.32-205.63-319.71
EPS (Diluted)-0.91-1.61-5.34-35.88-36.72-162.32-205.63-319.71
EBITDA-1.65-2.00-2.66-3.36-2.90-3.05-1.95-2.13
Non-Operating Income (Expense)0.010.010.010.010.010.010.010.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.030.030.070.470.040.220.040.04
Shares Outstanding2.191.580.500.120.090.020.020.01
Market Capitalization3.983.313.446.733.221.687.401.81

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments8.235.031.810.017.510.113.820.61
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.360.591.130.300.620.560.100.02
Total Current Assets8.595.622.930.318.130.673.920.64
Net Property, Plant & Equipment0.070.120.020.070.210.280.350.00
Total Investments and Advances0.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.000.000.00
Total Assets8.675.742.960.388.340.954.280.64
Short Term Debt Incl. Current Port. of LT Debt0.060.050.010.660.100.150.090.00
Accounts Payable1.840.901.411.290.921.230.250.29
Other Current Liabilities0.750.691.270.041.430.850.480.20
Total Current Liabilities2.641.642.701.992.442.230.810.49
Long Term Debt0.010.070.000.010.070.180.250.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities2.661.712.702.012.522.411.060.49
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity6.014.030.26-1.625.82-1.453.210.15
Total Shareholders Equity6.014.030.26-1.625.82-1.453.210.15
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity6.014.030.26-1.625.82-1.453.210.15
Total Liabilities & Stockholders Equity8.675.742.960.388.340.954.280.64
Book Value Per Share12.07214.842,481.95-2,112,202.061,109,725.03-277,405.68613,154.6929,178.92
Tangible Book Value Per Share12.07214.842,481.95-2,112,202.061,109,725.07-277,405.74613,154.8329,178.92
Full-Time Employees4447922-
Price to Book Ratio0.391.840.511.077.004.77--
Return on Assets-166.00-188.78-366.83-73.80-200.28-184.37-140.98-
Return on Equity-238.17-382.52-1,002.46-153.45-426.35-548.02-205.81-
Return on Invested Capital-198.51-200.02-5,033.59--157.95--99.89-2,819.85
Quick Ratio3.253.431.090.163.320.304.861.31
Current Ratio3.253.431.090.163.320.304.861.31

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-9.66-11.96-8.21-13.04-3.22-9.30-4.82-3.46-4.31
Depreciation0.000.000.000.060.050.070.070.000.00
Other Funds (Non Cash)0.650.840.042.160.570.700.150.421.48
Funds from Operations-9.01-11.11-8.16-10.82-2.60-8.53-4.59-3.04-2.83
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.410.93-0.451.681.510.220.890.160.46
Cash from Operating Activities-10.41-10.19-8.61-9.14-1.08-8.31-3.71-2.88-2.37
Capital Expenditures-0.00-0.000.00-0.01-0.000.00-0.000.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.00-3.840.000.000.00
Purchase of Investments0.000.000.000.000.00-3.840.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.00-0.000.00-0.01-0.00-3.84-0.000.00-0.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock16.2413.3911.8311.74-0.2315.500.004.982.99
Repurchase of Common Pref Stock0.000.000.000.00-0.120.000.000.000.00
Sale of Common Pref Stock16.2413.3911.8311.74-0.1115.500.004.982.99
Proceedsfrom Stock Options22.1813.3911.0711.73-0.1115.100.004.982.99
Issuance or Reduction of Debt, Net0.000.000.001.251.240.24-0.001.110.00
Change in Long Term Debt0.000.000.000.00-0.010.24-0.001.110.00
Issuance of Long Term Debt0.000.000.000.000.240.350.061.140.19
Reduction of Long Term Debt0.000.000.000.00-0.25-0.11-0.07-0.03-0.19
Net Financing Active Other Cash Flow-0.00-0.00-0.00-2.050.010.000.000.000.00
Other Financing Activities Uses-0.00-0.00-0.00-3.18-0.030.000.000.000.00
Cash from Financing Activities16.2413.3911.8310.951.0115.75-0.006.092.99
Net Change in Cash5.833.203.221.80-0.083.59-3.713.210.61
Free Cash Flow-10.42-10.19-8.61-9.15-1.09-8.31-3.71-2.88-2.37
Preferred Dividends (Cash Flow)-0.00-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments10.9511.058.234.055.123.28
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.390.230.360.640.450.65
Total Current Assets11.3311.288.594.705.583.93
Net Property, Plant & Equipment0.050.060.070.090.100.11
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets11.3811.348.674.785.674.04
Short Term Debt Incl. Current Port. of LT Debt0.040.060.060.050.050.05
Accounts Payable0.530.301.841.321.301.36
Other Current Liabilities0.530.430.751.390.961.37
Total Current Liabilities1.100.792.642.762.312.78
Long Term Debt0.000.000.010.030.040.06
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.100.792.662.792.352.84
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity10.2810.546.011.993.321.21
Total Shareholders Equity10.2810.546.011.993.321.21
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity10.2810.546.011.993.321.21
Total Liabilities & Stockholders Equity11.3811.348.674.785.674.04
Book Value Per Share4.706.6512.0717.0737.2564.22
Tangible Book Value Per Share4.706.6512.0717.0737.2564.22
Full-Time Employees--4---
Price to Book Ratio0.390.190.573.380.971.40
Return on Assets-113.27-141.84-166.00-219.61-157.55-217.11
Return on Equity-142.02-185.67-238.17-397.84-248.95-468.00
Return on Invested Capital-15.98-18.95-44.15-166.04-85.92-241.17
Quick Ratio10.3014.213.251.702.411.41
Current Ratio10.3014.213.251.702.411.41

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.64-2.00-2.66-3.36-2.89-3.05
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)0.050.040.080.480.050.23
Funds from Operations-1.60-1.95-2.58-2.88-2.84-2.81
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.15-1.73-0.390.57-0.331.08
Cash from Operating Activities-1.45-3.69-2.97-2.31-3.17-1.74
Capital Expenditures0.000.00-0.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.346.507.151.255.01-0.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.346.507.151.255.01-0.01
Proceedsfrom Stock Options1.346.507.157.19-0.93-0.01
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.000.000.000.00-0.00
Other Financing Activities Uses0.00-0.000.000.000.00-0.00
Cash from Financing Activities1.346.507.151.255.01-0.01
Net Change in Cash-0.102.824.17-1.071.84-1.75
Free Cash Flow-1.45-3.69-2.97-2.31-3.17-1.74

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.1M-327.22K
2026-10-15-0.1M-324.23K
2026-09-30-0.1M-329.31K
2026-09-15-0.1M-345.10K
2026-08-31-0.1M-184.76K
2026-08-14-0.1M-178.80K
2026-07-31-0.1M-62.34K
2026-07-15-0.1M-66.94K
2026-06-30-0.1M-105.80K
2026-06-15-0.1M-82.22K
2026-05-29-0.1M-79.35K
2026-05-15-0.1M-83.92K
2026-04-307.46%0.1M1.4M154.31K
2026-04-159.33%0.1M1.4M390.55K
2026-03-317.92%0.1M1.4M359.67K
2026-03-137.44%0.1M1.4M395.75K
2026-02-279.52%0.1M1.4M394.70K
2026-02-1311.02%0.2M1.4M386.46K
2026-01-3037.00%0.1M0.4M312.38K
2026-01-156.76%0.0M0.4M74.02K

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-12SCHEDULE 13GSEC
2026-11-048-KCurrent report2026-11-04SEC
2026-09-28ARSAnnual report to security holders. 2025-12-31SEC
2026-09-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-04SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-13SCHEDULE 13G/ASEC
2026-06-188-KCurrent report2026-06-18SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-13SCHEDULE 13G/ASEC
2026-02-13SCHEDULE 13G/ASEC
2026-02-10SCHEDULE 13G/ASEC
2026-02-048-KCurrent report2026-02-04SEC
2026-01-30EFFECTEffectiveness filing by commission orderSEC
2026-01-30CORRESPSEC
2026-01-3010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-01-308-KCurrent report2026-01-29SEC
2026-01-30424B5SEC
2026-01-30S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-01-30S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-01-30UPLOADUpload SubmissionSEC
2026-01-288-KCurrent report2026-01-28SEC
2026-01-218-KCurrent report2026-01-21SEC
2026-01-168-KCurrent report2026-01-15SEC
2026-01-158-KCurrent report2026-01-15SEC
2026-01-098-KCurrent report2026-01-09SEC
2026-01-09424B5SEC
2026-01-088-KCurrent report2026-01-08SEC
2025-12-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-01-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
DekaBank Deutsche Girozentrale2.36%
HRT FINANCIAL LP1.63%
JANE STREET GROUP, LLC1.41%
VANGUARD CAPITAL MANAGEMENT LLC1.21%
CITADEL ADVISORS LLC0.91%
COMMONWEALTH EQUITY SERVICES, LLC0.57%
MORGAN STANLEY0.49%
GEODE CAPITAL MANAGEMENT, LLC0.46%
LPL Financial LLC0.30%
Cranbrook Wealth Management, LLC0.19%

Funds

Fund% owned
WisdomTree International SmallCap Dividend Fund37.24%
Xtrackers International Real Estate ETF34.49%
WisdomTree Europe SmallCap Dividend Fund16.93%
WisdomTree Dynamic International SmallCap Equity Fund14.14%
WisdomTree International High Dividend Fund8.86%
Wilmington Real Asset Fund3.50%
VANGUARD EXTENDED MARKET INDEX FUND1.21%
First Trust Developed Markets ex-US Small Cap AlphaDEX Fund1.10%
Fidelity Extended Market Index Fund0.42%
Fidelity Series Total Market Index Fund0.04%

OakChart. GRI. Cached 15 minutes. Terms

Some panels did not load: insider.